These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 33091668

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.
    Li S, Wu B, Zheng X, Wang C, Zhao J, Sun H, Sun X, Tang Z, Yuan H, Chen L, Ma X.
    Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709
    [Abstract] [Full Text] [Related]

  • 25. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
    Ran F, Liu Y, Liu M, Zhang D, Wang P, Dong J, Tang W, Zhao G.
    Bioorg Chem; 2019 Aug; 89():102943. PubMed ID: 31031018
    [Abstract] [Full Text] [Related]

  • 26. Discovery of 1-Amino-1H-imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitors.
    Ma C, Li Q, Zhao M, Fan G, Zhao J, Zhang D, Yang S, Zhang S, Gao D, Mao L, Zhu L, Li W, Xu G, Jiang Y, Ding Q.
    J Med Chem; 2021 Nov 11; 64(21):16242-16270. PubMed ID: 34672559
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N, Li X, Shi Y, Ping L, Wu L, Fu K, Feng L, Zheng X, Song Y, Pan Z, Zhu J.
    Oncotarget; 2015 Jun 20; 6(17):15122-36. PubMed ID: 25944695
    [Abstract] [Full Text] [Related]

  • 30. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
    Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, Coraggio M, Dong L, Eigenbrot C, Erickson R, Ghilardi N, Hau J, Katewa A, Kohli PB, Lee W, Lubach JW, McKenzie BS, Ortwine DF, Schutt L, Tay S, Wei B, Reif K, Liu L, Wong H, Young WB.
    J Med Chem; 2018 Mar 22; 61(6):2227-2245. PubMed ID: 29457982
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series.
    Liu Q, Batt DG, Chaudhry C, Lippy JS, Pattoli MA, Surti N, Xu S, Carter PH, Burke JR, Tino JA.
    Bioorg Med Chem Lett; 2018 Oct 01; 28(18):3080-3084. PubMed ID: 30097367
    [Abstract] [Full Text] [Related]

  • 35. Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes.
    Liu J, Guiadeen D, Krikorian A, Gao X, Wang J, Babu Boga S, Alhassan AB, Yu W, Selyutin O, Yu Y, Anand R, Xu J, Kelly J, Duffy JL, Liu S, Yang C, Wu H, Cai J, Bennett C, Maloney KM, Tyagarajan S, Gao YD, Fischmann TO, Presland J, Mansueto M, Xu Z, Leccese E, Zhang-Hoover J, Knemeyer I, Garlisi CG, Stivers P, Brandish PE, Hicks A, Kim R, Kozlowski JA.
    Bioorg Med Chem Lett; 2020 Sep 01; 30(17):127390. PubMed ID: 32738973
    [Abstract] [Full Text] [Related]

  • 36. Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
    Ma B, Metrick CM, Gu C, Hoemberger M, Bajrami B, Bame E, Huang J, Mingueneau M, Murugan P, Santoro JC, Tang H, Wang T, Hopkins BT.
    Bioorg Med Chem Lett; 2022 Mar 15; 60():128549. PubMed ID: 35041943
    [Abstract] [Full Text] [Related]

  • 37. Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.
    Hopkins BT, Bame E, Bell N, Bohnert T, Bowden-Verhoek JK, Bui M, Cancilla MT, Conlon P, Cullen P, Erlanson DA, Fan J, Fuchs-Knotts T, Hansen S, Heumann S, Jenkins TJ, Gua C, Liu Y, Liu Y, Lulla M, Marcotte D, Marx I, McDowell B, Mertsching E, Negrou E, Romanowski MJ, Scott D, Silvian L, Yang W, Zhong M.
    Bioorg Med Chem; 2021 Aug 15; 44():116275. PubMed ID: 34314938
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S, Dammeijer F, Hendriks RW.
    Mol Cancer; 2018 Feb 19; 17(1):57. PubMed ID: 29455639
    [Abstract] [Full Text] [Related]

  • 40. Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory Activity.
    Qiu H, Ali Z, Bowlan J, Caldwell R, Gardberg A, Glaser N, Goutopoulos A, Head J, Johnson T, Maurer C, Georgi K, Grenningloh R, Fang Z, Morandi F, Rohdich F, Schmidt R, Follis AV, Sherer B.
    ChemMedChem; 2021 Dec 14; 16(24):3653-3662. PubMed ID: 34582626
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.